Protara Therapeutics
TARA
33 hedge funds and large institutions have $18.4M invested in Protara Therapeutics in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 14 reducing their positions, and 5 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5.05% less ownership
Funds ownership: 57.74% → 52.69% (-5.1%)
6% less funds holding
Funds holding: 35 → 33 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
45% less capital invested
Capital invested by funds: $33.2M → $18.4M (-$14.8M)
50% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$60.7K |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$53.6K |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$37.1K |
| 4 |
VF
Virtu Financial
New York
|
+$36.9K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$8.15K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$781K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$599K |
| 3 |
PA
Perceptive Advisors
New York
|
-$342K |
| 4 |
DAM
DLD Asset Management
New York
|
-$264K |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$141K |
TARA Hedge Fund Activity: Q2 2022 in Review
33 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q2 2022, worth a combined $18.4M — down 45% from $33.2M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of TARA and 3 opened new positions — a net loss of 2 holders — while 14 trimmed existing stakes and 7 added.
The largest buyer was Renaissance Technologies, adding an estimated $60.7K. The largest seller was Goldman Sachs, exiting entirely with an estimated $781K sold.
- 33 institutional investors held Protara Therapeutics (TARA) as of Q2 2022, down from 35 in Q1 2022.
- Funds reported $18.4M of Protara Therapeutics stock for Q2 2022, down 45% quarter-over-quarter.
- 3 funds opened new Protara Therapeutics positions in Q2 2022 and 5 closed out, a net change of -2 holders.
- The largest Protara Therapeutics buyer in Q2 2022 was Renaissance Technologies, an estimated $60.7K added.
- The largest Protara Therapeutics seller in Q2 2022 was Goldman Sachs, an estimated $781K sold.
Based on aggregated 13F filings for Q2 2022.